The Global Hydronephrosis Therapies Market to grow at a CAGR of 9.14% during the period 2019-2023.
The report covers the present scenario and the growth prospects of the hydronephrosis therapies market. To calculate the market size, the report considers the revenue generated by the sale of drugs for the treatment of hydronephrosis across the globe.The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
One trend affecting this market is the increasing awareness of kidney diseases. Kidney diseases are the major causes of hydronephrosis. However, early-stage kidney disease is typically asymptomatic and may not notice any symptoms, which, in turn, leads to low levels of awareness in people with CKD.
According to the report, one driver influencing this market is the driven by growing prevalence of kidney diseases that result in a higher incidence of hydronephrosis. Hydronephrosis is caused by kidney related diseases such as UTIs, CKDs, and kidney stones. According to the CDC, around 30 million people in the US are affected by CKD, which is likely to augment the growth of the global hydronephrosis treatment market. Furthermore, the increasing prevalence of ESRD, another kidney related disorder, will drive the demand for treatment of hydronephrosis across the period of forecast.
Further, the report states that one challenge affecting this market is the availability of alternate therapies. The growth of the market is impeded by the fact that despite having medications for the treatment of the underlying cause of hydronephrosis, there are several alternative procedures for the management of hydronephrosis.
Key questions answered in this report
What will the market size be in 2023 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the Key vendors in this market space?
What are the market opportunities and threats faced by the Key vendors?
What are the strengths and weaknesses of the Key vendors?
Growing prevalence of kidney diseases that result in a higher incidence of hydronephrosis
Availability of alternate therapies
Increasing awareness of kidney diseases
F. Hoffmann-La Roche
Teva Pharmaceutical Industries
Key Topics Covered:
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPE
Market segmentation analysis
PART 04: MARKET SIZING
Market sizing 2018
Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
Bargaining power of buyers
Bargaining power of suppliers
Threat of new entrants
Threat of substitutes
Threat of rivalry
PART 06: MARKET SEGMENTATION BY PRODUCT
Market segmentation by product
Comparison by product
Antibiotic therapy - Market size and forecast 2018-2023
Other therapies - Market size and forecast 2018-2023